'Egfr mutations' presentation slideshows

Tyrosine Kinase Inhibitors in non-small cell lung cancer

Giuseppe Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliated Branches. Tyrosine Kinase Inhibitors in non-small cell lung cancer. Estimated Cancer Death Rates in the United States 2009 Men 292,540; Women 269,800. Lung and bronchus 30% Prostate 9% Colon and rectum 9% Pancreas 6%

1.93k views • 97 slides

New Frontiers in Pathology

New Frontiers in Pathology. Case #7 August 3, 2012 Michael H. Roh, MD, PhD University of Michigan Health System. Disclosure Information. The speaker has no relationship representing a possible conflict of interest with respect to the content of this presentation. History.

577 views • 43 slides

EGFR gene mutation testing in NSCLC

EGFR gene mutation testing in NSCLC. Rachel Butler All Wales Molecular Genetics Laboratory. Benefits of stratified medicine. Reduce adverse reactions Reduce morbidity and patient distress Reduce associated costs Improve patient response through correct dose or effective therapy

420 views • 31 slides

Integrating Molecular Pathology Services in the West Midlands

Integrating Molecular Pathology Services in the West Midlands. Jennie Bell CMGS/ACC Spring meeting 14 th April 2010. Personalised Medicine. The Cancer Cell. Lung cancer cell. Cancer cells acquire the capacity for autonomous and dysregulated proliferation

492 views • 30 slides

Integrating Molecular Pathology Services in the West Midlands

Integrating Molecular Pathology Services in the West Midlands. Jennie Bell CMGS/ACC Spring meeting 14 th April 2010. Personalised Medicine. The Cancer Cell. Lung cancer cell. Cancer cells acquire the capacity for autonomous and dysregulated proliferation

419 views • 30 slides

Development of an EGFR/KRAS testing service for Non-Small Cell Lung Cancer (NSCLC)

Development of an EGFR/KRAS testing service for Non-Small Cell Lung Cancer (NSCLC). Joel Tracey 1 , Caroline Clark 1 , Christine Bell 1 , Keith Kerr 2 , Marianne Nicholson 3 , Aileen Osborne 1 , Zosia Miedzybrodzka 1 , Kevin Kelly 1

544 views • 24 slides

Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers

Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers. Michelle Wood , Hood Mugalassi, Justyna Tull, Linda Meredith, Rachel Butler Institute of Medical Genetics, University Hospital Wales, Cardiff. Lung cancer is the leading cause of cancer deaths.

315 views • 21 slides

781 views • 21 slides

H. Mugalaasi 1 , J. Davies 2 , L Medley 2 , D Talbot 2 , R. Brito 1 , R. Butler 1

Analysis of the Epidermal Growth Factor Receptor and K-Ras genes in patients with Non-small Cell Lung Cancer. H. Mugalaasi 1 , J. Davies 2 , L Medley 2 , D Talbot 2 , R. Brito 1 , R. Butler 1 1 All Wales Molecular Genetics Laboratory, Cardiff 2 Oxford Radcliffe Hospitals Trust. Overview.

292 views • 18 slides

531 views • 12 slides

300 views • 12 slides

308 views • 11 slides

First line gefitinib in EGFR mutation positive NSCLC in an Israeli cohort: unmet expectations

First line gefitinib in EGFR mutation positive NSCLC in an Israeli cohort: unmet expectations. Epidermal growth factor receptor (EGFR) mutations occur in approximately 10-25% of metastatic non-small cell lung carcinoma (NSCLC)

270 views • 1 slides